Guggenheim on Larimar (LRMR): 'With multiple near-term catalysts on the horizon, we see substantial upside potential'

March 19, 2026 12:57 PM

Guggenheim analyst Yatin Suneja reiterated a Buy rating and $26.00 price target on Larimar Therapeutics (NASDAQ: LRMR).The analyst comments "Following ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found